Efficacy of pitavastatin alone and in combination with ezetimibe on lipid profile in type II diabetes patients on biguanide therapy.

Not Applicable

Recruiting

• Conditions: Hyper(dys)lipidemia; Diabetes type II

• Registration Number: JPRN-UMIN000047286
• Lead Sponsor: BUHSC(K)

Brief Summary

This study proved that combination therapy of pitavastatin 2 mg and ezetimibe 10 mg did not show superior efficacy compared to therapy with pitavastatin 4 mg alone on lipid profile in type II diabetes. Even though the results were noticeable when means of all the parameters were compared, the difference between pre and post treatment numbers was not statistically significant.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2022-05-15
• Study Start: 2023-06-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 75

Inclusion Criteria

Not provided

Exclusion Criteria

Pregnancy & lactation; patients on other drugs for diabetes type II or insulin; over 65 years of age; on antibiotics, calcium channel blockers or thyroxine; CKD,CLD or thyroid disease.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Identification of effective lipid inhibitor(s) therapy in type II diabetics on biguanides.

Secondary Outcome Measures

Name	Time	Method
Correlation between glycemic and lipid parameters and groups of drugs